Suthanthiran and Strom (Aug. 11 issue)1 “discourage the use of organs from donors seropositive for the hepatitis C virus [HCV] for grafting in recipients who are seronegative for the virus.” In the setting of renal transplantation, in which effective alternative renal-replacement therapy is available, this guideline is not adequate to prevent HCV infection and thus exposes patients to unacceptable risks. The authors' figure of 5 percent for the prevalence of chronic hepatitis due to HCV after kidney transplantation is optimistically low. Lau et al. found that among 100 patients undergoing kidney transplantation, 18 were seropositive for HCV. . .
ASJC Scopus subject areas